Pediatric acute GVHD: clinical phenotype and response to upfront steroids

Area of Science:

• Hematology
• Pediatric Oncology
• Immunology

Background:

• Acute graft-versus-host disease (GVHD) is a significant complication following allogeneic stem cell transplantation.
• Understanding the clinical phenotype and risk factors in pediatric patients is crucial for optimizing treatment strategies.
• Current methods for risk stratification may not fully capture the complexities of acute GVHD in children.

Purpose of the Study:

• To evaluate the clinical phenotype of acute GVHD in a large cohort of pediatric patients.
• To assess the predictive value of initial GVHD grade and the Minnesota GVHD Risk Score on treatment response and outcomes.
• To identify factors influencing treatment response and transplant-related mortality in pediatric acute GVHD.

Main Methods:

• Retrospective analysis of 370 pediatric patients with acute GVHD treated between 1990 and 2016.
• Examination of GVHD clinical stage, grade, and response to prednisone (60 mg/m²/day PO) at day 28.
• Utilized the Minnesota GVHD Risk Score for risk stratification and multivariable analysis to identify predictors of response and mortality.

Main Results:

• Overall response (complete response + partial response) at day 28 was 65% (CR 52%; PR 13%).
• Initial GVHD grade did not predict day 28 response, but the Minnesota GVHD Risk Score did (68% SR-GVHD vs. 48% HR-GVHD, p < 0.01).
• High-risk GVHD and HLA-mismatched unrelated donor grafts were associated with lower response rates and increased transplant-related mortality.

Conclusions:

• The Minnesota GVHD Risk Score is a superior predictor of steroid failure and transplant-related mortality in pediatric acute GVHD compared to initial GVHD grade.
• Risk stratification using the Minnesota GVHD Risk Score is valuable for pediatric acute GVHD studies.
• Inclusion of pediatric patients in novel acute GVHD treatment trials is essential.